Lori Lawley
Director of Finance/CFO at LUMOS PHARMA, INC.
Net worth: 35 287 $ as of 30/03/2024
Profile
Lori Lawley is currently the Chief Financial Officer & Secretary at Lumos Pharma, Inc. Prior to this, she worked as a Vice President-Finance & Controller at NewLink Genetics Corp.
from 2018 to 2020.
She also served as a Senior Manager at Ernst & Young LLP from 2014 to 2015.
Ms. Lawley completed her undergraduate and graduate degrees at McCombs School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LUMOS PHARMA, INC.
0.15% | 31/03/2024 | 12,513 ( 0.15% ) | 35 287 $ | 30/03/2024 |
Lori Lawley active positions
| Companies | Position | Start |
|---|---|---|
| LUMOS PHARMA, INC. | Director of Finance/CFO | 03/07/2021 |
Former positions of Lori Lawley
| Companies | Position | End |
|---|---|---|
| LUMOS PHARMA, INC. | Comptroller/Controller/Auditor | 29/02/2020 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 31/03/2015 |
Training of Lori Lawley
| McCombs School of Business | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LUMOS PHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
- Stock Market
- Insiders
- Lori Lawley
